SERA PROGNOSTICS, INC. - 10-Q Summary (Q3 2025)
Business Context and Reporting Period
This Quarterly Report on Form 10-Q covers the period ended September 30, 2025. Sera Prognostics, Inc. is a women's health company focused on developing and commercializing blood-based biomarker tests, primarily the PreTRM test, which predicts the risk of preterm birth. The company operates as a single segment and is classified as an emerging growth company and a smaller reporting company.
Key Financial Metrics
| Metric | Q3 2025 | Q3 2024 | 9M 2025 | 9M 2024 |
|---|---|---|---|---|
| Revenue | $16,000 | $29,000 | $71,000 | $53,000 |
| Net Loss | $(7,814,000) | $(7,919,000) | $(24,047,000) | $(24,319,000) |
| Operating Expenses | $8,996,000 | $8,891,000 | $27,621,000 | $27,265,000 |
| Cash & Equivalents | $4,081,000 | $2,684,000 | As of Sept 30, 2025 | |
| Marketable Securities | $98,303,000 | $64,166,000 | As of Sept 30, 2025 | |
| Total Liquidity | $102,384,000 | $66,850,000 | As of Sept 30, 2025 | |
| Accumulated Deficit | $(303,841,000) | $(271,215,000) | As of Sept 30, 2025 |
Note: All figures in thousands except per share data. Revenue is minimal as the company is in the commercialization phase.
Material Changes vs. Prior Period
- Capital Raise: In February 2025, the company completed an underwritten public offering, raising approximately $53.6 million in net proceeds through the sale of Class A common stock and pre-funded warrants. This significantly increased total assets and liquidity compared to the prior year.
- Revenue: Q3 2025 revenue decreased to $16,000 from $29,000 in Q3 2024. However, revenue for the nine months ended September 30, 2025, increased to $71,000 from $53,000 in the prior year period.
- Operating Expenses: Total operating expenses remained relatively flat quarter-over-quarter ($8.996M vs $8.891M). Research and Development (R&D) expenses decreased by $218,000 in Q3 2025, primarily due to a reduction in clinical study costs as the PRIME study wound down. Selling and marketing expenses increased by $411,000 due to strategic hiring of commercial personnel.
- Investment Income: Other income, net, increased to $1.168 million in Q3 2025 from $948,000 in Q3 2024, driven by higher interest income on marketable securities.
Guidance, Outlook, and Risks
- Commercialization Strategy: Management is expanding its commercial team, having hired a Chief Commercial Officer in Q2 2025 and field sales representatives in Q3 2025. The focus is on specific geographies to drive adoption of the PreTRM test.
- Clinical Evidence: The company is leveraging positive results from the AVERT PRETERM TRIAL and the PRIME study (presented in Jan 2025) to support payer contracts. The PRIME study showed a 25% reduction in neonatal morbidity and mortality in the modified intent-to-treat population.
- Liquidity Runway: Management believes current cash and cash equivalents are sufficient to fund operations through 2028.
- Risks:
- Reimbursement: Significant risk exists regarding third-party payer coverage and reimbursement rates for the PreTRM test. Many payers currently do not reimburse for low-risk preterm birth screening.
- Regulatory: While a federal court vacated the FDA's final rule on Laboratory Developed Tests (LDTs) in March 2025, the regulatory landscape remains uncertain. Future legislative or regulatory changes could require premarket approval.
- Customer Concentration: The company relies on a limited number of direct customers, including Elevance Health, for a significant portion of revenue.
- Macroeconomic: Risks include inflation, supply chain disruptions, and potential tariffs on imported medical diagnostic materials.
Investor Verification Checklist
- Reimbursement Status: Verify the current in-network status and reimbursement rates with major commercial payers and Medicaid programs.
- PRIME Study Publication: Confirm the timeline for the full publication of PRIME study data in a peer-reviewed journal, as this is critical for commercial adoption.
- Capital Efficiency: Monitor the burn rate relative to the $102.4 million liquidity position to validate the 2028 runway projection.
- Regulatory Developments: Track any new legislative or FDA actions regarding the regulation of LDTs following the March 2025 court decision.
- Commercial Hiring Impact: Assess the return on investment for the new commercial hires and the timeline for revenue growth in targeted geographies.